The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Open accessAbstract
Use of highly pure antigens to improve vaccine safety has led to reduced vaccine immunogenicity and efficacy. This has led to the need to use adjuvants to improve vaccine immunogenicity. The ideal adjuvant should maximize vaccine immunogenicity without compromising tolerability or safety. Unfortunately, adjuvant research has lagged behind other vaccine areas such as antigen discovery, with the consequence that only a very limited number of adjuvants based on aluminium salts, monophosphoryl lipid A and oil emulsions are currently approved for human use. Recent strategic initiatives to support adjuvant development by the National Institutes of Health should translate into greater adjuvant choices in the future. Mechanistic studies have been valuable for better understanding of adjuvant action, but mechanisms of adjuvant toxicity are less well understood. The inflammatory or danger-signal model of adjuvant action implies that increased vaccine reactogenicity is the inevitable price for improved immunogenicity. Hence, adjuvant reactogenicity may be avoidable only if it is possible to separate inflammation from adjuvant action. The biggest remaining challenge in the adjuvant field is to decipher the potential relationship between adjuvants and rare vaccine adverse reactions, such as narcolepsy, macrophagic myofasciitis or Alzheimer’s disease. While existing adjuvants based on aluminium salts have a strong safety record, there are ongoing needs for new adjuvants and more intensive research into adjuvants and their effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., & Krieg, A. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2879 · Cited by 1,477
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Sutton, C., Brereton, C., Keogh, B., Mills, K. H. G., & Lavelle, E. C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060285 · Cited by 1,010
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
Self-citationDidierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K., & Osterhaus, A. (1984) · Nature · doi:10.1038/308457a0 · Cited by 708
Aluminum compounds as vaccine adjuvants
Gupta, R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00008-8 · Cited by 623
Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.3.1617 · Cited by 585
Cited by
Progress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 282
Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16347-w · Cited by 161
Honorato, L., Bonilla, J. J. A., Valdez, A. F., Frases, S., Araújo, G. R. D. S., Sabino, A. L. R. D. N., da Silva, N. M., Ribeiro, L., Ferreira, M. D. S., Kornetz, J., et al. (2024) · mSphere · doi:10.1128/msphere.00467-24 · Cited by 28
Metadata
- Authors
- Petrovsky, N.
- Venue
- Drug Safety
- Published
- 2015-10-08
- Volume
- 38
- Issue
- 11
- Pages
- 1059-1074
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W1895518456
- Cited by
- 366
- References
- 125
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. https://app.cochat.ai/papers/10.1007/s40264-015-0350-4
- The paper
- Petrovsky, N. (2015). Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Safety. https://doi.org/10.1007/s40264-015-0350-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
